Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window HOUSTON -- The ...

Testosterone therapy, no matter how it is delivered, raises the 6-month risk of venous thromboembolism (VTE) regardless of whether the men who take it have low levels of the hormone, a new ...

A new population-based study suggests that the duration of testosterone replacement therapy is an important factor to consider when assessing the risks of venous thromboembolism (VTE) associated with ...

(HealthDay News) — Testosterone therapy doesn’t appear to increase the risk of venous thromboembolism (VTE), according to a study published online in the Mayo Clinic Proceedings. “In 2014, the [U.S.] ...

Testosterone therapy in the absence of polycythemia was not associated with an increased risk for major adverse cardiovascular events or venous thromboembolism. Men on testosterone therapy who ...

Annual costs of VTE in the United States are substantial and have previously been estimated to be as high as $69.3 billion. 6,7 A study by Mahan et al in 2012 was performed to assess annual US ...

Rivaroxaban demonstrated similar efficacy as standard therapy but was associated with a significantly reduced rate of major bleeding among patients with symptomatic venous thromboembolism.

Please provide your email address to receive an email when new articles are posted on . Researchers characterized this as a “significant incidence” of new VTE; however, they noted most patients could ...

There is decreased risk for venous thromboembolism in women aged 50 to 64 years receiving hormone therapy and statin therapy. Statin therapy is associated with a decreased risk for venous ...

Pfizer and Bristol-Myers Squibb have reported that an extra year of treatment with their anticoagulant Eliquis (apixaban) safely reduces long-term risk in patients suffering from venous ...

BOSTON — New-age dabigatran etexilate (Pradaxa, Boehringer Ingelheim) was noninferior to old-guard warfarin for long-term, extended antithrombotic therapy in a trial of patients who had already ...

Use of postoperative venous thromboembolism to predict disease-specific survival in cancer patients. Screening for cardiac dysfunction and cardiovascular risk factors in childhood cancer survivors ...